This analyst is excited about the company's prospects.
Compare ANAB Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: AnaptysBio
A phoenix may well rise from the ashes of a disappointing clinical trial.
The company's leading drug candidate failed to meet its primary endpoint in a phase 2 clinical trial.
There was some encouraging news from across the Atlantic.
Perhaps no news is bad news for the ambitious biotech.
The biotech got a sharp upward shift in recommendation and target price from a prominent analyst.
Rule Breaker Investing: David's Biggest Losers Volume 6
The beaten-up biopharma provided an update that revved up interest in its pipeline.
Key clinical trial results this quarter will determine the better buy.
This antibody drug developer can be had for fire-sale prices.